The mpn Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mpn Hub cannot guarantee the accuracy of translated content. The mpn and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The MPN Hub is an independent medical education platform, sponsored by AOP Health and GSK, and supported through an educational grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mpn content recommended for you
Should JAK2 VAF testing be implemented as routine in risk assessment and disease monitoring in MPN?
Featured:
Mary McMullinDuring the European Hematology Association (EHA) 2023 Hybrid Congress, the MPN Hub was pleased to speak to Mary McMullin, Queen's University Belfast, Belfast, UK. We asked, Should JAK2 variant allele frequency (VAF) testing be implemented as routine in risk assessment and disease monitoring in myeloproliferative neoplasms (MPN)?
Should JAK2 VAF testing be implemented as routine in risk assessment and disease monitoring in MPN?
In this video interview, McMullin provides the argument against the use of JAK2 VAF testing as routine in JAK2-positive MPN. McMullin discusses the aims and targets for therapy and considers whether JAK2 VAF status influences treatment choice. Other clinical indicators such as blood count are noted and compared for their value against JAK2 VAF testing in overall management strategies. McMullin concludes by summarizing the potential negative impacts VAF testing could have on patient morale and the impracticality of implementing it as routine.